Search RHCG Website
Select your language

Scottish paediatric and adolescent infection and immunology network pathway for nMABs for non-hospitalised adolescents with COVID-19

exp date isn't null, but text field is

Infectious Disease


Neutralising monoclonal antibodies (nMABs) are recommended as a treatment option through routine commissioning for non-hospitalised ‘at risk’ adults and children (aged 12 years and above) with COVID-19.

Coronavirus » Interim clinical commissioning policy: neutralising monoclonal antibodies or antivirals for non-hospitalised patients with COVID-19 (

The first nMAB available for non-hospitalised patients is Sotrovimab (Xevudy) which both blocks viral entry into healthy cells and clears cells infected with SARS-CoV-2. It became available in limited quantities from Dec 2021 for those considered to have the highest risk of progression to severe disease

Editorial Information

Last reviewed: 29 March 2022

Next review: 29 March 2024

Author(s): Dr Conor Doherty

Version: 03/03/2022

Approved By: Scottish Paediatric and Adolescent Infection and Immunology Network